Commonwealth Equity Services’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.63M Buy
29,117
+2,957
+11% +$154K ﹤0.01% 2307
2026
Q1
$1.25M Buy
26,160
+2,885
+12% +$126K ﹤0.01% 2415
2025
Q4
$899K Buy
23,275
+16,352
+236% +$624K ﹤0.01% 2663
2025
Q3
$244K Sell
6,923
-280
-4% -$10.1K ﹤0.01% 3804
2025
Q2
$260K Buy
+7,203
New +$239K ﹤0.01% 3719
2023
Q2
Sell
-6,631
Closed -$238K 3911
2023
Q1
$238K Buy
+6,631
New +$246K ﹤0.01% 3166

Other funds holding RPRX

Commonwealth Equity Services's RPRX Position: Q2 2026 in Review

Commonwealth Equity Services increased its Royalty Pharma (RPRX) stake by 11% in Q2 2026, buying an estimated $154K and bringing the position to 29,117 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

Commonwealth Equity Services first reported a position in RPRX in Q1 2023 and has held it in 6 quarters since. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Commonwealth Equity Services held 29,117 shares of Royalty Pharma worth $1.63M as of Q2 2026.
  • Commonwealth Equity Services bought 2,957 Royalty Pharma shares in Q2 2026, an estimated $154K.
  • Royalty Pharma made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #2307 holding.
  • Commonwealth Equity Services first reported a position in Royalty Pharma in Q1 2023 and has held it in 6 quarters since.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.